The new Omicron subvariant CH.1.1, which has been detected in 67 countries including Thailand, can evade immunity produced by long-acting antibody (LAAB) vaccines but its rate of transmission is low, according to the Department of Medical Sciences says.
Dr Supakit Sirilak, the department chief, said there is concern that CH.1.1 might might prove detrimental to the efficiency of the LAAB shots that are used for those who have a compromised immune system, such as those with chronic kidney disease, cancer and organ transplant patients.
